Papers [Regulatives / Guidelines]

posted by Mahmoud  – Jordan, 2021-09-17 13:31 (81 d 23:05 ago) – Posting: # 22580
Views: 797

Dear all

Dr Anders Fuglsang discussed in his paper

Mitigation of the convergence issues associated with semi-replicated bioequivalence data. Pharmaceutical Statistics. 2021;1–3
used the proc mixed in RTR/TRR/RRT design in ABE

I think that using proc mixed to fit RTR/TRR/RRT design is not suitable, because in most cases proc mixed produced Estimated G matrix is not positive definite.

So proc GLM recommended by FDA and Emea is more appropriate in the Semi-replicated designs


Edit: Post moved. [Helmut]

Complete thread:

 Admin contact
21,788 posts in 4,557 threads, 1,548 registered users;
online 7 (0 registered, 7 guests [including 5 identified bots]).
Forum time: Wednesday 11:36 CET (Europe/Vienna)

There is no adequate defense, except stupidity,
against the impact of a new idea.    Percy Williams Bridgman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz